Advertisement

Topics

More Positives for PCSK9 inhibitors and the LDL-C Hypothesis

10:47 EDT 14 Mar 2018 | Medscape

The co-investigator for the ODYSSEY study of alirocumab discusses which patients will benefit most from the expensive biologic and why the mortality reduction finding comes with qualifiers.
theheart.org on Medscape

Original Article: More Positives for PCSK9 inhibitors and the LDL-C Hypothesis

NEXT ARTICLE

More From BioPortfolio on "More Positives for PCSK9 inhibitors and the LDL-C Hypothesis"

Advertisement
Quick Search
Advertisement
Advertisement